235 related articles for article (PubMed ID: 25438341)
1. Chronic blockade of endothelin A and B receptors using macitentan in experimental renovascular disease.
Tullos NA; Stewart NJ; Davidovich R; Chade AR
Nephrol Dial Transplant; 2015 Apr; 30(4):584-93. PubMed ID: 25438341
[TBL] [Abstract][Full Text] [Related]
2. Disparate effects of single endothelin-A and -B receptor blocker therapy on the progression of renal injury in advanced renovascular disease.
Chade AR; Stewart NJ; Peavy PR
Kidney Int; 2014 Apr; 85(4):833-44. PubMed ID: 24352153
[TBL] [Abstract][Full Text] [Related]
3. Endothelin-A receptor blockade slows the progression of renal injury in experimental renovascular disease.
Kelsen S; Hall JE; Chade AR
Am J Physiol Renal Physiol; 2011 Jul; 301(1):F218-25. PubMed ID: 21478482
[TBL] [Abstract][Full Text] [Related]
4. Selective ETA vs. dual ETA/B receptor blockade for the prevention of sunitinib-induced hypertension and albuminuria in WKY rats.
Mirabito Colafella KM; Neves KB; Montezano AC; Garrelds IM; van Veghel R; de Vries R; Uijl E; Baelde HJ; van den Meiracker AH; Touyz RM; Danser AHJ; Versmissen J
Cardiovasc Res; 2020 Aug; 116(10):1779-1790. PubMed ID: 31593221
[TBL] [Abstract][Full Text] [Related]
5. Vascular Endothelial Growth Factor and Podocyte Protection in Chronic Hypoxia: Effects of Endothelin-A Receptor Antagonism.
Harvey TW; Engel JE; Chade AR
Am J Nephrol; 2016; 43(2):74-84. PubMed ID: 26930122
[TBL] [Abstract][Full Text] [Related]
6. Endothelin-a receptor antagonism after renal angioplasty enhances renal recovery in renovascular disease.
Chade AR; Tullos N; Stewart NJ; Surles B
J Am Soc Nephrol; 2015 May; 26(5):1071-80. PubMed ID: 25377076
[TBL] [Abstract][Full Text] [Related]
7. A dual blocker of endothelin A/B receptors mitigates hypertension but not renal dysfunction in a rat model of chronic kidney disease and sleep apnea.
Morales-Loredo H; Jones D; Barrera A; Mendiola PJ; Garcia J; Pace C; Murphy M; Kanagy NL; Gonzalez Bosc LV
Am J Physiol Renal Physiol; 2019 May; 316(5):F1041-F1052. PubMed ID: 30810064
[TBL] [Abstract][Full Text] [Related]
8. Dual endothelin receptor antagonists contrast the effects induced by endothelin-1 on cultured human microvascular endothelial cells.
Soldano S; Paolino S; Pizzorni C; Trombetta AC; Montagna P; Brizzolara R; Corallo C; Giordano N; Sulli A; Cutolo M
Clin Exp Rheumatol; 2017; 35(3):484-493. PubMed ID: 28134077
[TBL] [Abstract][Full Text] [Related]
9. Dual Endothelin-A/Endothelin-B Receptor Blockade and Cardiac Remodeling in Heart Failure With Preserved Ejection Fraction.
Valero-Munoz M; Li S; Wilson RM; Boldbaatar B; Iglarz M; Sam F
Circ Heart Fail; 2016 Nov; 9(11):. PubMed ID: 27810862
[TBL] [Abstract][Full Text] [Related]
10. Novel dual endothelin receptor antagonist macitentan reverses severe pulmonary arterial hypertension in rats.
Kunita-Takanezawa M; Abe K; Hirooka Y; Kuwabara Y; Hirano K; Oka M; Sunagawa K
J Cardiovasc Pharmacol; 2014 Nov; 64(5):473-80. PubMed ID: 25084082
[TBL] [Abstract][Full Text] [Related]
11. Biopolymer-delivered vascular endothelial growth factor improves renal outcomes following revascularization.
Guise E; Engel JE; Williams ML; Mahdi F; Bidwell GL; Chade AR
Am J Physiol Renal Physiol; 2019 May; 316(5):F1016-F1025. PubMed ID: 30892933
[TBL] [Abstract][Full Text] [Related]
12. Pharmacology of macitentan, an orally active tissue-targeting dual endothelin receptor antagonist.
Iglarz M; Binkert C; Morrison K; Fischli W; Gatfield J; Treiber A; Weller T; Bolli MH; Boss C; Buchmann S; Capeleto B; Hess P; Qiu C; Clozel M
J Pharmacol Exp Ther; 2008 Dec; 327(3):736-45. PubMed ID: 18780830
[TBL] [Abstract][Full Text] [Related]
13. Mesenchymal Stem Cell-Derived Extracellular Vesicles Improve the Renal Microvasculature in Metabolic Renovascular Disease in Swine.
Eirin A; Zhu XY; Jonnada S; Lerman A; van Wijnen AJ; Lerman LO
Cell Transplant; 2018 Jul; 27(7):1080-1095. PubMed ID: 29954220
[TBL] [Abstract][Full Text] [Related]
14. Systemic biopolymer-delivered vascular endothelial growth factor promotes therapeutic angiogenesis in experimental renovascular disease.
Chade AR; Williams ML; Guise E; Vincent LJ; Harvey TW; Kuna M; Mahdi F; Bidwell GL
Kidney Int; 2018 Apr; 93(4):842-854. PubMed ID: 29273331
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic and pharmacodynamic evaluation of macitentan , a novel endothelin receptor antagonist for the treatment of pulmonary arterial hypertension.
Sidharta PN; Krähenbühl S; Dingemanse J
Expert Opin Drug Metab Toxicol; 2015 Mar; 11(3):437-49. PubMed ID: 25604973
[TBL] [Abstract][Full Text] [Related]
16. Comparison of acute and chronic antioxidant interventions in experimental renovascular disease.
Chade AR; Krier JD; Rodriguez-Porcel M; Breen JF; McKusick MA; Lerman A; Lerman LO
Am J Physiol Renal Physiol; 2004 Jun; 286(6):F1079-86. PubMed ID: 14722019
[TBL] [Abstract][Full Text] [Related]
17. Vascular Effects of Endothelin Receptor Antagonists Depends on Their Selectivity for ETA Versus ETB Receptors and on the Functionality of Endothelial ETB Receptors.
Iglarz M; Steiner P; Wanner D; Rey M; Hess P; Clozel M
J Cardiovasc Pharmacol; 2015 Oct; 66(4):332-7. PubMed ID: 25992919
[TBL] [Abstract][Full Text] [Related]
18. Renal, retinal and cardiac changes in type 2 diabetes are attenuated by macitentan, a dual endothelin receptor antagonist.
Sen S; Chen S; Feng B; Iglarz M; Chakrabarti S
Life Sci; 2012 Oct; 91(13-14):658-68. PubMed ID: 22525377
[TBL] [Abstract][Full Text] [Related]
19. Antioxidant intervention blunts renal injury in experimental renovascular disease.
Chade AR; Rodriguez-Porcel M; Herrmann J; Zhu X; Grande JP; Napoli C; Lerman A; Lerman LO
J Am Soc Nephrol; 2004 Apr; 15(4):958-66. PubMed ID: 15034098
[TBL] [Abstract][Full Text] [Related]
20. Celecoxib, but not indomethacin, ameliorates the hypertensive and perivascular fibrotic actions of cyclosporine in rats: role of endothelin signaling.
El-Mas MM; Helmy MW; Ali RM; El-Gowelli HM
Toxicol Appl Pharmacol; 2015 Apr; 284(1):1-7. PubMed ID: 25656942
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
